NEWS

Posters to be displayed at Dec. 4-8 conference address introduction of Phase 2 study of investigational drug lasofoxifene, its effect on breast cancer and lung and liver metastasis in an in vivo model, and oncologists’ perceptions of ESR1 mutations and biomarker testing. COLUMBUS, Ohio, Nov. 14, 2018 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals LLC, a privately […]

Linical Accelovance Group will serve as research partner for study that compares lasofoxifene to fulvestrant. COLUMBUS, Ohio, Oct. 09, 2018 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced the launch of a Phase 2 trial for the treatment of [...]

Biotechnology company will globally develop and commercialize drug for treatment of advanced metastatic breast cancer. COLUMBUS, OH–(Marketwired – Oct 31, 2017) – Sermonix Pharmaceuticals LLC, a privately held biotechnology company focused on the development and commercialization of female-specific oncology products, today announced its recent completion of a $4.2 million [...]

Accord allows Sermonix to globally develop and commercialize drug for treatment of advanced breast cancer COLUMBUS, OH–(Marketwired – Feb 28, 2017) – Sermonix Pharmaceuticals LLC, a privately held biotechnology company focused on the development and commercialization of female-specific oncology products, today announced it licensed worldwide rights to develop and [...]

Women’s Oncology Pharmaceutical Company Also Raises More Than $2 Million in Preferred Seed Funding Round  COLUMBUS, OH, (December 7, 2016) – Sermonix Pharmaceuticals LLC, a privately held biotechnology company focused on the development and commercialization of female-specific oncology products, today announced that it signed a licensing agreement through which Sermonix will gain exclusive [...]

 COLUMBUS, OH (November 28, 2016) – Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced that its poster on physician perceptions of estrogen agonist/antagonists in menopausal health has been accepted for presentation at the San Antonio Breast Cancer Symposium (SABC). The Dec. [...]

Sermonix Also to Present Poster on Physicians’ Perceptions of SERMs in Menopausal Health COLUMBUS, OH–(Marketwired – Sep 26, 2016) – Sermonix Pharmaceuticals Inc., a specialty pharmaceutical company focused on late-stage women’s health products, today announced that its exploratory analysis on sexual activity and orgasm frequency in menopause will be one of three [...]

COLUMBUS, OH–(Marketwired – Aug 3, 2016) – Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company focused on late-stage women’s health products, convened the inaugural meeting of its Oncology Steering Committee July 14th in New York City. The group, which included world-renowned experts focused on the prevention, diagnosis and treatment of breast cancer, [...]

  From the June 15th, 2016 New York Times: As a practicing obstetrician-gynecologist for 20 years, I saw firsthand how fear could be a very real factor in patient decision-making. Bisphosphonates are drugs that reduce osteoporotic fractures by suppressing bone turnover at a higher rate than normal. In rare cases, overpowering this natural remodeling process […]

Investment and New Board Leadership Will Support the Path to Commercialization for Investigational Drug, Lasofoxifene  COLUMBUS, OH (May 3, 2016) – Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company focused on the development and commercialization of emerging late-stage women’s health products, today announced Anthony H. Wild, Ph.D., as Chairman of the Board and also a [...]